

# Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer

This article was published in the following Dove Press journal:  
*Cancer Management and Research*

Yang Feng<sup>1,\*</sup>

Yaqi Li<sup>2,3,\*</sup>

Sanjun Cai<sup>2,3</sup>

Junjie Peng<sup>2,3</sup>

<sup>1</sup>Department of General Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, People's Republic of China; <sup>2</sup>Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, People's Republic of China; <sup>3</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China

\*These authors contributed equally to this work

**Background:** The type, abundance, and location of tumor-infiltrating lymphocytes (TILs) have been associated with prognosis in colorectal cancer (CRC). This study was conducted to assess the prognostic role of TILs and develop a nomogram for accurate prognostication of stage II CRC.

**Methods:** Immunohistochemistry was conducted to assess the densities of intraepithelial and stromal CD3+, CD8+, CD45RO+, and FOXP3+ TILs, and to estimate PD-L1 expression in tumor cells for 168 patients with stage II CRC. The prognostic roles of these features were evaluated using COX regression model, and nomograms were established to stratify patients into low- and high-risk groups and compare the benefit from adjuvant chemotherapy.

**Results:** In univariate analysis, patients with high intraepithelial or stromal CD3+, CD8+, CD45RO+ and FOXP3+ TILs were associated significantly with better relapse-free survival (RFS) and overall survival (OS), except for stromal CD45RO+ TILs. In multivariate analysis, patients with high intraepithelial CD3+ and stromal FOXP3+ TILs were associated with better RFS ( $p < 0.001$  and  $p = 0.032$ , respectively), while only stromal FOXP3+ TILs was an independent prognostic factor for OS ( $p = 0.031$ ). The nomograms were well calibrated and showed a c-index of 0.751 and 0.757 for RFS and OS, respectively. After stratifying into low- and high-risk groups, the high-risk group exhibited a better OS from adjuvant chemotherapy (3-year OS of 81.9% vs 34.3%,  $p = 0.006$ ).

**Conclusion:** These results may help improve the prognostication of stage II CRC and identify a high-risk subset of patients who appeared to benefit from adjuvant chemotherapy.

**Keywords:** CD3, CD8, FOXP3, stage II, adjuvant chemotherapy

## Introduction

5-fluorouracil-based adjuvant chemotherapy has been well established for patients with stage III colorectal cancer (CRC), but in stage II CRC, adjuvant chemotherapy is still hotly disputed considering the cost, toxicity, and limited survival benefit.<sup>1-4</sup>

A number of clinicopathological features (poor histological differentiation, T4 stage, <12 nodes harvested, high preoperative carcinoembryonic antigen (CEA) level, intestinal obstruction or perforation, and the presence of lymphovascular or perineural invasion) have been identified assisting the decision for adjuvant chemotherapy in stage II disease.<sup>1,5,6</sup> However, only T4 stage has been proven to help identify a specific subset of stage II CRC patients who could achieve survival benefit from adjuvant chemotherapy.<sup>7</sup> Besides, some polygene signatures have been widely explored,<sup>8,9</sup> but there is still a long way to put these results into clinical

Correspondence: Junjie Peng; Sanjun Cai  
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center  
Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong'an Road, Shanghai 200032, People's Republic of China  
Tel +86 1 801 731 7122;  
+86 1 390 181 5189  
Fax +86 215 417 5590  
Email pengjj67@hotmail.com;  
caisanjun\_sh@163.com

practice. Identifying novel biomarkers to filter out the high-risk group of stage II CRC which could benefit from adjuvant chemotherapy is badly needed.

Adaptive immune response has been proven to influence the biological behavior of tumor cells, and the immune microenvironment formed by the type, abundance, and location of immune cells within tumor tissues were found to be a better predictor of patient survival than traditional clinicopathological features.<sup>10</sup> Naito et al<sup>11</sup> first demonstrated that the infiltration of tumor nests by CD8+ T-cells was a novel prognostic factor contributing to a better survival in CRC. Thereafter, CD3+ tumor-infiltrating lymphocytes (TILs) have been identified to be associated with favorable prognosis and a lower risk of metachronous metastasis in CRC.<sup>12,13</sup> CD45RO+ TILs have also been reported to have prognostic significance. Pages et al<sup>14</sup> revealed that high levels of CD45RO+ TILs were correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. In early-stage CRC, patients with a strong infiltration of CD45RO+ T-cells exhibited an increased expression of T-helper 1 and cytotoxicity-related genes and helped predict tumor recurrence and survival.<sup>15</sup> Regulatory T-cells engage in the maintenance of immunological self-tolerance by actively suppressing self-reactive lymphocytes.<sup>16,17</sup> Nuclear transcription factor FOXP3, as a key regulatory gene for the development of regulatory T-cells, has been proven to be associated with improved survival in CRC.<sup>18</sup> Therapeutic antibodies targeting the programmed cell death 1 protein (PD-1) and the programmed death-ligand 1 protein (PD-L1) have been proven to be effective in a number of cancer types.<sup>19,20</sup> Li et al<sup>21</sup> revealed higher expressions of PD-1 and PD-L1 correlated with better prognosis of CRC patients. The objective of the current study was to assess and compare the prognostic role of PD-L1 and different types of TILs in stage II CRC and construct a nomogram for better prognostication, and to identify the subgroup of stage II CRC patients who can actually benefit from chemotherapy.

## Methods

### Study group

We 1:1 matched 84 recurrent stage II CRC patients to patients without recurrence, rendering 168 patients for analysis in our study. CRC tissue blocks were sent for next-generation sequencing (NGS) at Burning Rock Dx Corporation, Shanghai. No patients received preoperative therapy before radical surgery. Patients did not tolerate

adequate course of adjuvant chemotherapy was excluded. All patients were regularly followed-up with a median follow-up time at 54.4 months (range 11.3–95.8 months). Informed consent had been obtained and this study was approved by the institutional review board of the Fudan University Shanghai Cancer Center.

### Immunohistochemistry (IHC)

Immunohistochemically staining was performed according to standard protocol. Briefly, paraffin-embedded samples were cut into 4 µm sections and placed on polylysine-coated slides. Paraffin sections were baked overnight at 58°C, dewaxed in xylene, rehydrated through a graded series of ethanol, quenched for endogenous peroxidase activity in 0.3% hydrogen peroxide for 15 mins. Antigen retrieval was performed by high-pressure cooking in citrate buffer (pH=6.0) for about 20 mins, then allowed to cool to room temperature, blocking the nonspecific antibody binding sites in 5% normal goat serum for 2 hrs. Sections were incubated at 37°C for 1.5 hrs with rabbit polyclonal antibody against CD3 (1:400, Abcam, ab16669, USA), CD8 (1:400, Cell Signaling Technology, 70306S, USA), CD45RO (1:400, Dako, DK-2600 Glostrup, Denmark), FOXP3 (1:400, Abcam, ab20034, USA), and PD-L1 (1:100, Abcam, ab205921), in a moist chamber. Biotinylated secondary antibody was performed using the EnVision+System-HRP (AEC) (K4005, Dako, Glostrup, Denmark). Subsequently, sections were counterstained with hematoxylin (Sigma-Aldrich, St Louis, MO, USA). TMA slides were scanned by an automated scanning microscope and counted by Image-Pro Plus software (IPP; produced by Media Cybernetics Corporation, USA). Epithelial and stromal areas were calculated separately. Five independent visual fields (at ×400 magnification), representing the most abundant lymphocytic infiltrates, were selected for each patient sample, and we used the mean density to stratify variables into dichotomous data for statistical analysis. PD-L1 expression score was the sum of the cytoplasmic and membrane scores.<sup>22</sup> Cytoplasmic expression level was scored as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong), and membrane expression level was scored as 0 (absent) or 1 (present). PD-L1 scores 2/3/4 were counted as high, scores 0/1 as low.

### Statistical analysis

We used chi-square tests or Fisher's exact test to compare immunological biomarkers expression levels. Univariate and

multivariate analyses were conducted using the Cox regression model. Nomograms were established by R software and the model performance for predicting outcome was evaluated by Harrell's concordance index (c-index). X-tile 3.6.1 software<sup>23</sup> (Yale University, New Haven, CT, USA) was used to determine the optimal cutoff values, stratifying the patients into low- and high-risk groups. Kaplan–Meier curves were drawn and log-rank tests were used to compare the survival data between different groups. *p*-values were accepted at <0.05 and all analyses were performed with the R 2.15.3 software.

## Results

### Immunohistochemical characteristics

Epithelial and in stromal TILs were evaluated separately. Utilizing tissue microarray (TMA), we quantified CD3+, CD8+, CD45RO+, and FOXP3+ cells by automatic imaging analysis on 168 stage II CRC samples. Representative immunohistochemical findings are demonstrated in Figure 1. Densities of each T-cell subset (cells/mm<sup>2</sup>) were distributed as follows: intraepithelial CD3+ (mean 84; range 0–352), stromal CD3+ (mean 376; range 0–1380), intraepithelial CD8+ (mean 60; range 0–344), stromal CD8+ (mean 220; range 0–1120), intraepithelial CD45RO+ (mean 76; range 0–384), stromal CD45RO+ (mean 344; range 0–1600), intraepithelial FOXP3+ (mean 16; range 0–132), and stromal FOXP3+ (mean 132; range 0–600). Seventy-two patients were identified as PD-L1 low, and 96 patients were identified as PD-L1 high.

### Correlation of immune biomarkers with clinicopathological and molecular features


Molecular features were available in 129 patients who successfully underwent NGS. As shown in Table 1, patients with high intraepithelial CD3+, CD45RO+, and stromal FOXP3+ TILs had a significantly higher incidence of normal preoperative CEA (*p*=0.010, 0.013, and 0.017, respectively). Patients with high intraepithelial FOXP3+ TILs underwent less adjuvant chemotherapy (*p*=0.019). More colon disease was observed in patients with high intraepithelial CD8+ TILs. Patients with high intraepithelial CD45RO+ and stromal CD8+ TILs had a significantly lower incidence of neural invasion (*p*=0.043 and 0.046, respectively). More T4 tumors were found in patients with high intraepithelial CD8+ TILs (*p*=0.025). Patients with high intraepithelial CD45RO+ TILs had a significantly higher

incidence of adequate lymph nodes harvested (*p*=0.005). Patients with high intraepithelial CD8+ and CD45RO+ TILs had a significantly higher incidence of MSI-high (*p*=0.017 and 0.002, respectively). More *ERBB2* mutation were observed in patients with high intraepithelial CD45RO+, FOXP3+, and stromal CD45RO+ TILs (*p*=0.019, 0.020, and 0.012, respectively). More *TP53* mutation were found in patients with high intraepithelial CD8+ and CD45RO+ TILs (*p*=0.034 and 0.025, respectively). No significant differences were observed for gender, age, histology type, grade, vascular invasion, *APC* mutation, *BRAF* mutation, *KRAS* mutation, *NRAS* mutation, *POLE* mutation, *PIK3CA* mutation, and *PTEN* mutation.

### Prognostic factors

In univariate analysis (Table 2), for tumor features, CEA was significantly associated with better relapse-free survival (RFS) and overall survival (OS) (*p*<0.001 and *p*=0.015, respectively). Number of lymph nodes harvested (LNH) were significantly associated with better OS (*p*=0.012). Grade reached marginal significance for both RFS and OS (*p*=0.055 and *p*=0.068, respectively). For molecular features, *BRAF* and *PTEN* mutation were found to be significantly associated with better OS (*p*=0.007 and *p*=0.034, respectively), whereas *BRAF* mutation only reached marginal significance for RFS (*p*=0.081). For Immune biomarkers, high intraepithelial or stromal CD3+, CD8+, CD45RO+, FOXP3+ TILs were significantly associated with better RFS and OS (all *p*<0.05), except for high stromal CD45RO+ TILs (*p*=0.110). PD-L1 was not associated with RFS or OS (*p*=0.574 and *p*=0.820, respectively). A multivariate model was developed to test independent prognostic factors for RFS and OS (Table 3). In the first model (Model A, *n*=168), only tumor features and immune biomarkers with a *p*<0.100 in univariate analysis were included. CEA (*p*=0.040; RR, 1.591; 95% CI, 1.022–2.495), intraepithelial CD3+ TILs (*p*<0.001; RR, 0.192; 95% CI, 0.094–0.395), and stromal FOXP3+ TILs (*p*=0.032; RR, 0.526; 95% CI, 0.292–0.974) were found to be the strongest prognostic factors for RFS, whereas LNH (*p*=0.010; RR, 0.374; 95% CI, 0.178–0.784) and stromal FOXP3+ TILs (*p*=0.031; RR, 0.249; 95% CI, 0.071–0.878) were proven to be independent prognostic factors for OS. The second model added molecular features (Model B, *n*=129) for analysis, intraepithelial CD3+ (*p*<0.001; RR, 0.179; 95% CI, 0.082–0.391) and stromal FOXP3+ TILs (*p*=0.015;





**Figure 1** Representative examples of immunohistochemical findings for CD3, CD8, CD45RO, FOXP3, and PD-L1 (original magnification,  $\times 400$ ). (**A,B**) Positive for intraepithelial and stromal CD3; (**C,D**) positive for intraepithelial and stromal CD8; (**E,F**) positive for intraepithelial and stromal CD45RO; (**G,H**) positive for intraepithelial and stromal FOXP3; (**I,J**) positive for cytoplasmic and membranous PD-L1.

RR, 0.425; 95% CI, 0.214–0.845) retained significance for RFS. While for OS, stromal FOXP3+ TILs ( $p=0.016$ ; RR, 0.155; 95% CI, 0.034–0.703), LNH ( $p=0.038$ ; RR, 0.436;

95% CI, 0.199–0.956), and *PTEN* mutation ( $p=0.001$ ; RR, 6.526; 95% CI, 2.149–19.815) were the strongest prognostic factors.

**Table 1** Clinicopathological and molecular features according to the densities of tumor-infiltrating lymphocytes and PD-L1 expression

Variables	Subgroup	No. of patients																			
		CD3e				CD8e				CD45ROe				FOXP3e				PD-L1			
		L	H	P		L	H	P		L	H	P		L	H	P		L	H	P	
Gender	Male	63	33	0.518	70	26	0.920	66	30	0.924	66	30	0.924	66	30	0.924	43	53		0.637	
	Female	43	29		53	19		49	23		49	23		49	23		29	43			
Age	<60	49	33	0.426	58	24	0.492	53	29	0.323	54	28	0.510	54	28	0.510	32	50		0.352	
	≥60	57	29		65	21		62	24		61	25		61	25		40	46			
CEA	<5.2ng/mL	64	50	0.010	78	36	0.061	71	43	0.013	73	41	0.079	73	41	0.079	49	65		0.962	
	≥5.2ng/mL	42	12		45	9		44	10		42	12		42	12		23	31			
Chemotherapy	No	41	31	0.196	55	17	0.483	47	25	0.503	42	30	0.019	42	30	0.019	27	45		0.271	
	Yes	65	31		68	28		68	28		73	23		73	23		45	51			
Location	Colon	52	38	0.150	59	31	0.023	56	34	0.069	62	28	0.896	62	28	0.896	39	51		0.893	
	Rectum	54	24		64	14		59	19		53	25		53	25		33	45			
Histology type	A	94	58	0.417	110	42	0.563	103	49	0.778	101	51	0.097	101	51	0.097	64	88		0.601	
	MA	12	4		13	3		12	4		14	2		14	2		8	8			
Grade	Poor	6	0	0.086	6	0	0.194	6	0	0.178	6	0	0.178	6	0	0.178	4	2		0.404	
	Well /moderate	100	62		117	45		109	53		109	53		109	53		68	94			
Vascular invasion	No	99	56	0.553	115	40	0.337	108	47	0.350	106	49	0.950	106	49	0.950	68	87		0.400	
	Yes	7	6		8	5		7	6		9	4		9	4		4	9			
Neural invasion	No	82	51	0.556	98	35	0.831	86	47	0.043	90	43	0.838	90	43	0.838	55	78		0.450	
	Yes	24	11		25	10		29	6		25	10		25	10		17	18			
pT	pT3	76	40	0.388	91	25	0.025	82	34	0.373	79	37	0.884	79	37	0.884	54	62		0.178	
	pT4	30	22		32	20		33	19		36	16		36	16		18	34			
LNH	<12	26	12	0.567	32	6	0.097	33	5	0.005	27	11	0.843	27	11	0.843	17	21		0.853	
	≥12	80	50		91	39		82	48		88	42		88	42		55	75			
MSI status	Low/MSS	74	43	0.212	89	28	0.017	84	33	0.002	81	36	0.103	81	36	0.103	51	66		0.121	
	high	5	7		5	7		3	9		5	7		5	7		2	10			
APC mutation	Wild-type	27	17	0.983	32	12	0.979	29	15	0.844	28	16	0.694	28	16	0.694	18	26		0.977	
	Mutant	52	33		62	23		58	27		58	27		58	27		35	50			

(Continued)

Table 1 (Continued).

Variables	Subgroup	No. of patients																													
		CD3e						CD8e						CD45ROe						FOX3e						PD-L1					
		L	H	P	L	H	P	L	H	P	L	H	P	L	H	P	L	H	P	L	H	P	L	H	P						
BRAF mutation	Wild type Mutant	73 6	48 2	0.483	88 6	33 2	0.889	80 7	41 1	0.273	79 7	42 1	0.268	49 4	72 4	0.716															
KRAS mutation	Wild type Mutant	41 38	28 22	0.718	51 43	18 17	0.844	47 40	22 20	0.861	44 42	25 18	0.575	31 22	38 38	0.374															
NRAS mutation	Wild type Mutant	75 4	47 3	1.000	90 4	32 3	0.388	81 6	41 1	0.426	81 5	41 2	1.000	49 4	73 3	0.445															
ERBB2 mutation	Wild type Mutant	73 6	44 6	0.536	88 6	29 6	0.086	83 4	34 8	0.019	82 4	35 8	0.020	51 2	66 10	0.121															
POLE mutation	Wild type Mutant	74 5	44 6	0.335	88 6	30 5	0.168	81 6	37 5	0.336	80 6	38 5	0.505	50 3	68 8	0.524															
PIK3CA mutation	Wild type Mutant	64 15	40 10	0.887	76 18	28 7	0.913	69 18	35 7	0.643	68 18	36 7	0.640	46 7	58 18	0.176															
PTEN mutation	Wild type Mutant	75 4	43 7	0.106	89 5	29 6	0.068	81 6	37 5	0.336	81 5	37 6	0.178	49 4	69 7	0.739															
TP53 mutation	Wild type Mutant	22 57	18 32	0.337	24 70	16 19	0.034	21 66	19 23	0.025	24 62	16 27	0.316	13 40	27 49	0.246															
Variables	Subgroup	No. of patients																													
		CD3s						CD8s						CD45ROs						FOX3s											
		L	H	P	L	H	P	L	H	P	L	H	P	L	H	P	L	H	P	L	H	P	L	H	P						
Gender	Male	58	38	0.748	62	34	0.742	54	42	0.203	61	35	0.750																		
	Female	46	26		49	23		48	24		44	28																			
Age	<60	52	30	0.752	50	32	0.194	45	37	0.156	47	35	0.203																		
	≥60	52	34		61	25		57	29		68	28																			
CEA	<5.2ng/mL	66	48	0.130	71	43	0.163	67	47	0.501	64	50	0.017																		
	≥5.2ng/mL	38	16		40	14		35	19		41	13																			
Chemotherapy	No	41	31	0.265	46	26	0.625	42	30	0.634	40	32	0.112																		
	Yes	63	33		65	31		60	36		65	31																			

(Continued)

Table 1 (Continued).

Variables	Subgroup	No. of patients															
		CD3s				CD8s				CD45ROs				FOXP3s			
		L	H	P		L	H	P		L	H	P		L	H	P	
Location	Colon Rectum	57 47	33 31	0.751		63 48	27 30	0.258		52 50	38 28	0.432		61 44	29 34	0.151	
		91 13	61 3	0.111		98 13	54 3	0.267		90 12	62 4	0.286		92 13	60 3	0.173	
Grade	Poor Well /moderate	6 98	0 64	0.084		5 106	1 56	0.665		5 97	1 65	0.405		5 100	1 62	0.412	
		99 5	56 8	0.081		105 6	50 7	0.133		93 9	62 4	0.571		98 7	57 6	0.557	
Vascular invasion	No Yes	82 22	51 13	0.896		93 18	40 17	0.046		80 22	53 13	0.847		80 25	53 10	0.151	
		73 31	43 21	0.732		74 37	42 15	0.383		72 30	44 22	0.612		72 33	44 19	0.863	
LNH	<12 ≥12	26 78	12 52	0.448		23 88	15 42	0.440		24 78	14 52	0.851		25 80	13 50	0.706	
		70 7	47 5	0.920		77 7	40 5	0.752		73 5	44 7	0.217		77 6	40 6	0.346	
MSI status	Low/MSS high	26 51	18 34	0.921		26 58	18 27	0.334		30 48	14 37	0.255		30 53	14 32	0.565	
		71 6	50 2	0.473		78 6	43 2	0.713		73 5	48 3	0.903		76 7	45 1	0.258	
KRAS mutation	Wild type Mutant	38 39	31 21	0.283		46 38	23 22	0.715		43 35	26 25	0.719		43 40	26 20	0.713	
		72 5	50 2	0.701		79 5	43 2	1.000		73 5	49 2	0.703		79 4	43 3	0.699	
ERBB2 mutation	Wild type Mutant	73 4	44 8	0.066		79 5	38 7	0.109		75 3	42 9	0.012		76 7	41 5	0.754	

(Continued)

Table 1 (Continued).

Variables	Subgroup	No. of patients			CD3s			CD8s			CD45ROs			FOXP3s		
		L	H	P	L	H	P	L	H	P	L	H	P	L	H	P
POLE mutation	Wild type	70	48	1.000	77	41	1.000	74	44	0.111	77	41	0.111	77	41	0.520
	Mutant	7	4		7	4		4	7		6	5		6	5	
PIK3CA mutation	Wild type	58	46	0.073	65	39	0.248	61	43	0.496	65	39	0.496	65	39	0.487
	Mutant	19	6		19	6		17	8		18	7		18	7	
PTEN mutation	Wild type	71	47	0.765	77	41	0.914	73	45	0.341	77	41	0.341	77	41	0.520
	Mutant	6	5		7	4		5	6		6	5		6	5	
TP53 mutation	Wild type	22	18	0.561	25	15	0.694	22	18	0.439	28	12	0.439	28	12	0.430
	Mutant	55	34		59	30		56	33		55	34		55	34	

**Note:** Molecular features were available in only 129 patients.  
**Abbreviations:** CD3e, intraepithelial CD3+ cells; CD3s, stromal CD3+ cells; CD8e, intraepithelial CD8+ cells; CD8s, stromal CD8+ cells; CD45ROe, intraepithelial CD45RO+ cells; CD45ROs, stromal CD45RO+ cells; FOXP3e, intraepithelial FOXP3+ cells; FOXP3s, stromal FOXP3+ cells; L, low; H, high; CEA, carcinoembryonic antigen; A, adenocarcinoma; MA, mucinous adenocarcinoma; LN, number of lymph nodes harvested; MSI, microsatellite instability; MSS, microsatellite stability.

# Nomogram construction, risk group stratification, and benefit from adjuvant chemotherapy

Variables with a *p*-value <0.10 in the multivariate analysis were included in nomogram construction. Three nomograms were constructed based on variables for RFS (nomogram A) and OS (nomogram B) in Model A and variables for OS (nomogram C) in Model B (see Figure 2), we did not establish a nomogram for RFS in Model B due to limited variables in the final model. Calibration curves were exhibited in Figure S1. For Model A, the nomograms were well calibrated and showed a c-index of 0.751 and 0.757 for RFS and OS, respectively. For Model B, the nomogram for OS was well calibrated and reached a c-index of 0.768. X-tile software was used to select the optimal cutoff values. After stratifying into low- and high-risk groups (Figure S2), for nomogram A, high-risk patients had a significantly worse RFS low-risk patients (5-year RFS, 16.1% vs 58.2%, *p*<0.001). For nomogram B and nomogram C, worse OS was observed in high-risk group compared with low-risk group (5-year OS, 60.5% vs 90.6%, *p*<0.001; 5-year OS, 45.0% vs 87.7%, *p*<0.001, respectively). The relationship between risk groups and benefit from adjuvant chemotherapy is illustrated in Figure 3. No significant differences for RFS were observed between chemo-treated and chemo-naïve patients in different risk groups (*p*=0.625 and 0.434, respectively). For nomogram B, in high-risk group, chemo-treated patients had a better OS versus chemo-naïve patients, which reached marginal significance (5-year OS, 71.1% vs 34.8%, *p*=0.105). For nomogram C, better OS was observed in chemo-treated patients compared with chemo-naïve patients (3-year OS, 81.9% vs 34.3%, *p*=0.006).

## Discussion

The therapeutic success of 5-fluorouracil-based adjuvant chemotherapy has been validated in stage III CRC, but not for patients with stage II disease.<sup>24,25</sup> Up to now, only one nomogram predicting recurrence in stage II CRC has been constructed in literature by Hoshino et al<sup>26</sup> which included sex, carcinoembryonic antigen, tumor location, tumor depth, lymphatic invasion, venous invasion, and number of lymph nodes studied, rendering a c-index of 0.64. In our study, we first introduced immune biomarkers into nomogram construction, achieving a c-index of overwhelming



**Table 2** Univariate analyses of factors associated with relapse-free and overall survival

Variables	RFS			OS		
	HR	95% CI	p	HR	95% CI	p
<b>Tumor features</b>						
Gender, female vs male	0.829	0.534–1.287	0.742	1.371	0.661–2.843	0.396
Age, ≥60 vs <60	1.258	0.814–1.942	0.301	1.679	0.793–3.554	0.176
CEA, ≥5.2 ng/mL vs <5.2 ng/mL	2.274	1.472–3.515	<0.001	2.468	1.189–5.122	0.015
Adjuvant chemotherapy, yes vs no	1.118	0.722–1.732	0.618	0.825	0.396–1.716	0.606
Location, rectum vs colon	1.335	0.867–2.054	0.189	1.188	0.573–2.462	0.643
Histology type, MA vs A	0.827	0.381–1.795	0.631	0.654	0.155–2.754	0.563
Grade, well/moderate vs poor	0.411	0.166–1.021	0.055	0.328	0.099–1.085	0.068
Vascular invasion, yes vs no	0.780	0.340–1.791	0.558	0.773	0.183–3.256	0.726
Neural invasion, yes vs no	0.934	0.548–1.592	0.802	0.403	0.122–1.332	0.136
pT, T4 vs T3	0.993	0.621–1.587	0.976	1.065	0.485–2.340	0.876
LNH, ≥12 vs <12	0.756	0.464–1.231	0.261	0.389	0.186–0.805	0.012
<b>Molecular features</b>						
MSI status, high vs low/MSS	0.770	0.310–1.915	0.574	0.699	0.165–2.962	0.627
APC mutation, M vs WT	0.988	0.593–0.645	0.962	2.173	0.819–5.765	0.119
BRAF mutation, M vs WT	2.111	0.912–4.888	0.081	4.399	1.507–12.842	0.007
KRAS mutation, M vs WT	1.110	0.687–1.792	0.671	0.870	0.399–1.894	0.725
NRAS mutation, M vs WT	0.795	0.250–2.531	0.698	0.045	0.000–71.101	0.410
ERBB2 mutation, M vs WT	0.833	0.335–2.074	0.695	0.326	0.044–2.410	0.272
POLE mutation, M vs WT	0.994	0.430–2.299	0.988	1.531	0.523–4.480	0.437
PIK3CA mutation, M vs WT	0.663	0.338–1.298	0.231	0.862	0.325–2.287	0.765
PTEN mutation, M vs WT	1.061	0.459–2.456	0.889	2.873	1.080–7.640	0.034
TP53 mutation, M vs WT	1.187	0.698–2.019	0.527	1.173	0.493–2.792	0.718
<b>Immune biomarkers, high vs low</b>						
CD3e	0.132	0.066–0.265	<0.001	0.276	0.105–0.726	0.009
CD8e	0.210	0.101–0.437	<0.001	0.253	0.076–0.835	0.024
CD45ROe	0.247	0.131–0.467	<0.001	0.287	0.100–0.825	0.020
FOXP3e	0.211	0.109–0.410	<0.001	0.195	0.059–0.644	0.007
PD-L1	1.134	0.731–1.761	0.574	0.918	0.442–1.910	0.820
CD3s	0.375	0.224–0.638	<0.001	0.356	0.145–0.874	0.024
CD8s	0.361	0.209–0.623	<0.001	0.191	0.058–0.630	0.007
CD45ROs	0.497	0.307–0.805	0.004	0.514	0.228–1.162	0.110
FOXP3s	0.257	0.148–0.444	<0.001	0.148	0.045–0.488	0.002

**Note:** Cox proportional hazards regression model, molecular features were available in only 129 patients.

**Abbreviations:** RFS, relapse-free survival; OS, overall survival; M, mutant; WT, wild type; CEA, carcinoembryonic antigen; A, adenocarcinoma; MA, mucinous adenocarcinoma; LNH, number of lymph nodes harvested; MSI, microsatellite instability; MSS, microsatellite stability; CD3e, intraepithelial CD3+ cells; CD3s, stromal CD3+ cells; CD8e, intraepithelial CD8+ cells; CD8s, stromal CD8+ cells; CD45ROe, intraepithelial CD45RO+ cells; CD45ROs, stromal CD45RO+ cells; FOXP3e, intraepithelial FOXP3+ cells; FOXP3s, stromal FOXP3+ cells.

0.751 and 0.757 for RFS and OS, respectively. Besides, the risk classification based on nomogram could identify a special high-risk subset of stage II CRC patients who may benefit from adjuvant chemotherapy.

Accumulating evidence suggests that effector/cytotoxic T-cells (CD3+<sup>12,13</sup> and CD8+<sup>11,27</sup>), memory T-cells (CD45RO+<sup>14,15</sup>), and regulatory T-cells (FOXP3+<sup>16,18</sup>) play important roles in antitumor immune response. Thus, the specific subsets of these TILs are thought to be

indicators of host immune response to tumor cells and might be a target for immunotherapy.<sup>28,29</sup> In the current study, we utilized a digitized, high-resolution image analysis system to count the number of TILs, and the mean densities of T-cell subsets were comparable with previous studies (CD3+,<sup>10,30</sup> CD8+,<sup>18,31</sup> CD45RO+,<sup>18,32</sup> and FOXP3+<sup>30,31</sup>). Previous studies have demonstrated the high density of CD3+, CD8+, CD45RO+, or FOXP3+ TILs with MSI-high.<sup>18,30,33,34</sup> In the current study, high

**Table 3** Multivariate Cox proportional model for predictors of relapse-free and overall survival

DFS				OS			
Prognostic features	HR	95% CI	p	Prognostic features	HR	95% CI	p
<b>Model A (N=168)</b>				<b>Model A (N=168)</b>			
CEA, $\geq 5.2$ ng/mL vs $< 5.2$ ng/mL	1.591	1.022–2.475	0.040	CEA, $\geq 5.2$ ng/mL vs $< 5.2$ ng/mL	2.080	0.995–4.349	0.052
CD3e, high vs low	0.192	0.094–0.395	$< 0.001$	LNH, $\geq 12$ vs $< 12$	0.374	0.178–0.784	0.010
CD8s, high vs low	0.600	0.338–1.064	0.080	CD8s, high vs low	0.325	0.093–1.143	0.080
FOXP3s, high vs low	0.526	0.292–0.974	0.032	FOXP3s, high vs low	0.249	0.071–0.878	0.031
<b>Model B (N=129)</b>				<b>Model B (N=129)</b>			
CD3e, high vs low	0.179	0.082–0.391	$< 0.001$	CD8e, high vs low	0.282	0.067–1.178	0.083
FOXP3s, high vs low	0.425	0.214–0.845	0.015	FOXP3s, high vs low	0.155	0.034–0.703	0.016
				LNH, $\geq 12$ vs $< 12$	0.436	0.199–0.956	0.038
				<i>PTEN</i> mutation, M vs WT	6.526	2.149–19.815	0.001

**Notes:** Cox proportional hazards regression model. Model A included tumor features and immune biomarkers with a  $p < 0.10$  in univariate analysis (N=168). Model B included tumor features, immune biomarkers, and molecular features with a  $p < 0.10$  in univariate analysis (N=129). A backward LR (likelihood ratio) elimination with a threshold of  $p = 0.10$  was presented in the final model.


**Abbreviations:** RFS, relapse-free survival; OS, overall survival; M, mutant; WT, wild type; CEA, carcinoembryonic antigen; LNH, number of lymph nodes harvested; CD3e, intraepithelial CD3+ cells; CD8e, intraepithelial CD8+ cells; CD8s, stromal CD8+ cells; FOXP3s, stromal FOXP3+ cells.

densities of CD45RO+ and CD8+ cells, but not that of CD3+ or FOXP3+ cells, are significantly associated with MSI-high. We used multivariate analysis to assess the prognostic roles of these immune biomarkers and found intraepithelial CD3+ TILs and stromal FOXP3+ TILs were the strongest prognostic factors for RFS, whereas only stromal FOXP3+ TILs were an independent prognostic factor for OS. Our study revealed patients with high intraepithelial CD3+ and stromal FOXP3+ TILs had a significantly higher incidence of normal preoperative CEA, which partially explained the good prognosis associated with these biomarkers. Although Li et al<sup>21</sup> concluded PD-L1 correlated with better prognosis in CRC patients, our study did not prove the prognostic role PD-L1, which is in agreement with Masugi's<sup>22</sup> study.

Despite numerous studies have demonstrated the prognostic roles of immune-related biomarkers using IHC, seldom have these studies involved molecular features for analysis. In our study, 129 patients successfully underwent NGS and classic mutations for CRC were evaluated for their prognostic roles. *KRAS* mutation and *PTEN* mutation were found to be significant factors for OS in univariate analysis, while only *PTEN* mutation was demonstrated as an independent prognostic factor in multivariate analysis after adjusting for clinicopathological features and immune biomarkers. *PTEN* is a candidate tumor suppressor and key negative regulator of

the PI3K pathway, involving in cell proliferation, migration, and survival.<sup>35</sup> Somatic mutations in *PTEN* were detected in about 6% of sporadic CRC, and *PTEN* mutation was found to be associated with proximal tumors, mucinous histology, MSI-H, CIMP-high, and *BRAF* mutation.<sup>36</sup> In our study, 8.5% *PTEN* mutation was observed, 36.4% of MSI-high patients were observed in *PTEN* mutation group compared with 6.8% in the wild-type group, which is in consistence with previous studies.<sup>36,37</sup> Recent reports suggest that *PTEN* exerts an important tumor suppressor role in colorectal carcinogenesis<sup>35</sup> and correlative analyses have associated loss of *PTEN* with poorer survival,<sup>38,39</sup> which is in agreement with our study.

Our study is limited as a retrospective study in nature, further validations from other institutions are merited. Secondly, we did not separate colon and rectal cancer for further study due to limited sample size. Moreover, considering intratumoral heterogeneity, we admit that our study might still fall short of capturing heterogeneity within tumor. Despite of these shortcomings, this is the largest study elucidating the prognostic roles of the densities of various types of TILs focusing on stage II CRC, and we first used nomogram to visualize the results and stratify patients into low- and high-risk groups. More importantly, it is easier for clinical use than signatures or other risk classification systems.




**Figure 2** Nomograms for 1-, 3-, and 5-year probabilities of survival. **(A)** Nomogram A predicting relapse-free survival based on Model A, with a c-index of 0.751; **(B)** nomogram B predicting overall survival based on Model B, with a c-index of 0.757; **(C)** nomogram C predicting overall survival based on Model C, with a c-index of 0.768.

**Abbreviations:** CEA, carcinoembryonic antigen; LNH, number of lymph nodes harvested; CD3e, intraepithelial CD3+ cells; CD8s, stromal CD8+ cells; CD8e, intraepithelial CD8+ cells; FOXP3s, stromal FOXP3+ cells.

In summary, we constructed nomograms which may help to predict RFS and OS in patients with stage II CRC.

Furthermore, we identified a high-risk subset of stage II CRC patients who appeared to benefit from adjuvant chemotherapy.



**Figure 3** Relationship between risk groups and benefit from adjuvant chemotherapy in stage II colorectal cancer patients. **(A)** Relapse-free survival based on nomogram A classification; **(B)** overall survival based on nomogram B classification; **(C)** overall survival based on nomogram C classification.

## Ethics approval and consent to participate

Informed consent had been obtained and this study was approved by the institutional review board of the Fudan

University Shanghai Cancer Center. The patient consent was written informed consent, and that this study was conducted in accordance with the Declaration of Helsinki.

## Abbreviation list

TILs, tumor-infiltrating lymphocytes; CRC, colorectal cancer; dMMR, deficient mismatch repair; pMMR, proficient mismatch repair; CEA, carcinoembryonic antigen; PD-1, programmed cell death 1 protein; PD-L1, programmed death-ligand 1 protein; NGS, next-generation sequencing; TMA, tissue microarray; RFS, relapse-free survival; OS, overall survival; LNH, lymph nodes harvested; NCCN, National Comprehensive Cancer Network; MSI, microsatellite instability; MSS, microsatellite stability; CD3e, intraepithelial CD3+ cells; CD3s, stromal CD3+ cells; CD8e, intraepithelial CD8+ cells; CD8s, stromal CD8+ cells; CD45ROe, intraepithelial CD45RO+ cells; CD45ROs, stromal CD45RO+ cells; FOXP3e, intraepithelial FOXP3+ cells; FOXP3s, stromal FOXP3+ cells.

## Author contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

## Disclosure

The abstract for this paper was accepted as poster presentation at the 2018 ASCO conference. The authors report no other potential conflicts of interest in this work.


## References

- Kucukzeybek Y, Dirican A, Demir L, et al. Adjuvant chemotherapy and prognostic factors in stage II colon cancer—izmir oncology group study. *Asian Pac J Cancer Prev*. 2015;16:2413–2418. doi:10.7314/apjcp.2015.16.6.2413
- Benson AB 3rd, Schrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol*. 2004;22:3408–3419. doi:10.1200/JCO.2004.05.063
- O'Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. *J Clin Oncol*. 2011;29:3381–3388. doi:10.1200/JCO.2010.34.3426
- Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. *Lancet*. 2007;370:2020–2029. doi:10.1016/S0140-6736(07)61866-2
- Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. *Dis Colon Rectum*. 2008;51:503–507. doi:10.1007/s10350-008-9246-z
- Okada K, Sadahiro S, Suzuki T, et al. The size of retrieved lymph nodes correlates with the number of retrieved lymph nodes and is an independent prognostic factor in patients with stage II colon cancer. *Int J Colorectal Dis*. 2015;30:1685–1693. doi:10.1007/s00384-015-2357-9
- Kumar A, Kennecke HF, Renouf DJ, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. *Cancer*. 2015;121:527–534. doi:10.1002/cncr.29072
- Gao S, Tibiche C, Zou J, et al. Identification and construction of combinatory cancer hallmark-based gene signature sets to predict recurrence and chemotherapy benefit in stage II colorectal cancer. *JAMA Oncol*. 2016;2:37–45. doi:10.1001/jamaoncol.2015.3413
- Tian X, Zhu X, Yan T, et al. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer. *Mol Oncol*. 2017;11:1544–1560. doi:10.1002/1878-0261.12117
- Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science*. 2006;313:1960–1964. doi:10.1126/science.1129139
- Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Res*. 1998;58:3491–3494.
- Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. *Gastroenterology*. 2009;137:1270–1279. doi:10.1053/j.gastro.2009.06.053
- Laghi L, Bianchi P, Miranda E, et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. *Lancet Oncol*. 2009;10:877–884. doi:10.1016/S1470-2045(09)70186-X
- Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. *N Engl J Med*. 2005;353:2654–2666. doi:10.1056/NEJMoa051424
- Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. *J Clin Oncol*. 2009;27:5944–5951. doi:10.1200/JCO.2008.19.6147
- Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol*. 2003;4:330–336. doi:10.1038/ni904
- Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science*. 2003;299:1057–1061. doi:10.1126/science.1079490
- Salama P, Phillips M, Griew F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. *J Clin Oncol*. 2009;27:186–192. doi:10.1200/JCO.2008.18.7229
- Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature*. 2014;515:568–571. doi:10.1038/nature13954
- Le DT, Durham JN. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*. 2017;357:409–413. doi:10.1126/science.aan6733
- Li Y, Liang L, Dai W, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. *Mol Cancer*. 2016;15:55. doi:10.1186/s12943-016-0539-x
- Masugi Y, Nishihara R, Yang J, et al. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. *Gut*. 2017;66:1463–1473. doi:10.1136/gutjnl-2016-311421
- Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res*. 2004;10:7252–7259. doi:10.1158/1078-0432.CCR-04-0713
- Kohne CH. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. *Lancet Oncol*. 2006;7:516–517.
- Sobrero A. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. *Lancet Oncol*. 2006;7:515–516. doi:10.1016/S1470-2045(06)70727-6
- Hoshino N, Hasegawa S, Hida K, et al. Nomogram for predicting recurrence in stage II colorectal cancer. *Acta Oncol*. 2016;55:1414–1417. doi:10.1080/0284186X.2016.1223881
- Chiba T, Ohtani H, Mizoi T, et al. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. *Br J Cancer*. 2004;91:1711–1717. doi:10.1038/sj.bjc.6602201




28. Zou W. Regulatory T cells, tumour immunity and immunotherapy. *Nat Rev Immunol.* **2006**;6:295–307. doi:10.1038/nri1806
29. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. *Lancet.* **2009**;373:673–683. doi:10.1016/S0140-6736(09)60404-9
30. Noshio K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. *J Pathol.* **2010**;222:350–366. doi:10.1002/path.2774
31. Suzuki H, Chikazawa N, Tasaka T, et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. *Cancer Immunol Immunother.* **2010**;59:653–661. doi:10.1007/s00262-009-0781-9
32. Lee WS, Park S, Lee WY, Yun SH, Chun HK. Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer. *Cancer.* **2010**;116:5188–5199. doi:10.1002/cncr.25293
33. Guidoboni M, Gafa R, Viel A, et al. Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. *Am J Pathol.* **2001**;159:297–304. doi:10.1016/S0002-9440(10)61695-1
34. Michel S, Benner A, Tariverdian M, et al. High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. *Br J Cancer.* **2008**;99:1867–1873. doi:10.1038/sj.bjc.6604756
35. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. *Cell.* **2000**;100:387–390. doi:10.1016/S0092-8674(00)80674-1
36. Day FL, Jorissen RN, Lipton L, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. *Clin Cancer Res.* **2013**;19:3285–3296. doi:10.1158/1078-0432.CCR-12-3614
37. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. *Nature.* **2005**;436:792. doi:10.1038/nature03934
38. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. *J Clin Oncol.* **2009**;27:5924–5930. doi:10.1200/JCO.2008.21.6796
39. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. *Clin Colorectal Cancer.* **2012**;11:143–150. doi:10.1016/j.clcc.2011.12.001

## Supplementary material



**Figure S1** Calibration of the nomograms for 1-, 3-, and 5-year probabilities of survival. The x-axis shows the nomogram-predicted survival at 1, 3, and 5 years, and the y-axis shows the observed actual survival and 95% confidence intervals. **(A)** Calibration of nomogram A; **(B)** calibration of nomogram B; **(C)** calibration of nomogram C.



**Figure S2** Survival curves comparing different risk groups. The patients were stratified into two groups according to the cutoff values generated by X-tile program. **(A)** Relapse-free survival based on nomogram A classification; **(B)** Overall survival based on nomogram B classification; **(C)** overall survival based on nomogram C classification.

## Cancer Management and Research

Dovepress

### Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>